Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 10, 2024

Interpretable Artificial Intelligence to Optimise Imatinib Use After Resection in Localised Gastrointestinal Stromal Tumours

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study
Lancet Oncol 2024 Jul 05;[EPub Ahead of Print], D Bertsimas, G Antonios Margonis, S Sujichantararat, A Koulouras, Y Ma, CR Antonescu, MF Brennan, J Martín-Broto, S Tang, P Rutkowski, ME Kreis, K Beyer, J Wang, E Bylina, P Sobczuk, A Gutierrez, B Jadeja, WD Tap, P Chi, S Singer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading